p21 and p53 Immunostaining and Survival following Systemic Chemotherapy for Urothelial Cancer

Publisher： Karger

E-ISSN： 1423-0399|69|3|174-180

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.69, Iss.3, 2002-10, pp. : 174-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

p53 Gene Mutation, Microsatellite Instability and Adjuvant Chemotherapy: Impact on Survival of 388 Patients with Dukes’ C Colon Carcinoma

By  

Oncology, Vol. 58, Iss. 1, 2000-01 ,pp. : 52-59

Karger

Access to resources Recommend Favorite

Significance of lymphovascular invasion in organ‐confined, node‐negative urothelial cancer of the bladder: data from the prospective p53‐MVAC trial

By  

BJU INTERNATIONAL, Vol. 116, Iss. 1, 2015-07 ,pp. : 44-49

John Wiley & Sons Inc

Access to resources Recommend Favorite

Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study

By  

Oncology, Vol. 91, Iss. 3, 2016-07 ,pp. : 127-134

Karger

Access to resources Recommend Favorite

Prognostic Value of Multidrug Resistance 1, Glutathione-S-Transferase-π and p53 in Advanced Nasopharyngeal Carcinoma Treated with Systemic Chemotherapy

By  

Oncology, Vol. 62, Iss. 4, 2002-07 ,pp. : 305-312

Karger

Access to resources Recommend Favorite

Comparative Survival Analysis of p53 Gene Mutations and Protein Accumulation in Colorectal Cancer

By  

Oncology, Vol. 55, Iss. 3, 1998-04 ,pp. : 249-257

Karger

Access to resources Recommend Favorite